Thriving biotech: three stocks building momentum
In this article, Dmytro Spilka explores three promising biotechs that have seen growth in the last year and why they may continue to garner interest.
List view / Grid view
Articles
Nanobodies that bind a component of the SARS-CoV-2 replication complex
Professors Piergiorgio Percipalle and Gennaro Esposito summarise their study which revealed two nanobodies that could inhibit a non-structural protein of SARS-CoV-2.
Analysing proteomics data to translate in vivo studies as early as possible
Dr Antal Szalay, CEO and Founder of Ultimate Medicine, explores how the analysis of omics data, especially metabolomics and proteomics, can provide researchers with vital insight that can inform the development of drugs for conditions associated with age.
mRNA vaccine technology – a promising platform for novel vaccine development
Dr Pushpanathan Muthuirulan explores why messenger RNA (mRNA) is advantageous for vaccine development and how the COVID-19 pandemic has accelerated its progress within the pharmaceutical industry.
Drug Target Review Flow Cytometry ebook 2021
This ebook includes articles on flow cytometry in drug discovery and how it is applied to leishmaniasis research. Also included is a piece on how flow cytometry is being used to support the translational research of immuno-oncology therapies.
Drug Target Review Upstream Bioprocessing ebook 2021
In this ebook, find an article on 3D tissue cultures from biopsy samples to evaluate the preservation of tissue-typical protein expressions as well as a piece on a new process analytical technology (PAT) system to assess N-glycosylation during upstream cell culture bioprocessing.
Drug Target Review – Issue 4 2021
This issue includes articles that discuss the development of long-term 3D tissue cultures from human biopsy samples, the application of flow cytometry in drug discovery and automation for upstream processing in a biologics manufacturing environment. Also included are features on informatics, proteomics and CRISPR.
Highlights from Drug Target Review’s Cell & Gene Therapy Advancements Online Summit
Here, we round up some of the key takeaways from the expert panel discussions at the Cell & Gene Therapy Advancements Online Summit.
Improving the safety of CRISPR for the clinic
Dr Danilo Maddalo from Genentech outlines the main benefits of CRISPR within the clinical realm and highlights some of the safety concerns that must be considered before CRISPR products reach patients.
“Off-the-shelf” immunotherapies for cancer
In this article, Drug Target Review's Victoria Rees explores a new method that could enable powerful immune cells to be produced in large quantities to treat a range of cancers.
Target safety assessments – identifying risk early
With an ever-increasing emphasis on minimising drug candidate attrition, scientists are focusing on target safety at earlier points in the research process. In this exclusive interview, Drug Target Review spoke with Dr Gordon Baxter, Chief Scientific Officer of Instem, to learn how target safety assessments can enable researchers to quickly…
Human iPSC-derived cardiomyocytes for cardiac proarrhythmic risk assessment
Following Drug Target Review's webinar supported by Eurofins, speaker Dr Verena Albert answers the questions posed by the audience during the live event.
Peptides: a promising alternative to opioids for chronic pain relief
In an exclusive with Drug Target Review, researchers at the University at Buffalo explain how they developed a novel peptide that could be a future treatment for chronic inflammatory pain.
Are computer simulations the future of rapid COVID-19 drug development?
Researchers have visualised SARS-CoV-2 protein dynamics using in silico methods. In this article, Navodya Roemer explains how a team from the University of Warwick developed a computational strategy that could assist scientists in the production of new treatments and drugs for COVID-19.
AI & Informatics: Drug discovery and development – industry survey infographic
View Drug Target Review's new infographic on the use of AI and informatics within early therapeutic development here.
